Anti-PD-L1/CD274 Antibody Rabbit Monoclonal

<strong>Anti-PD-L1/CD274 Antibody Rabbit Monoclonal</strong> <strong>Catalog number:</strong> B2020162 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 ug <strong>Molecular Weight or Concentration:</strong> NA <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Chen, L., & Han, X. (2015). Anti-PD-1/PD-L1 therapy in cancer: current status and future directions. *Journal of Clinical Oncology*, 33(17), 1974-1982. 2. Topalian, S. L., Hodi, F. S., & Brahmer, J. R. (2012). Targeting the PD-1/B7-H1 pathway to activate anti-tumor immunity. *Journal of Experimental Medicine*, 209(6), 1243-1254. 3. Garon, E. B., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. *New England Journal of Medicine*, 372(21), 2018-2028. 4. Brahmer, J. R., et al. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *New England Journal of Medicine*, 373(2), 123-135. 5. Zhang, Y., et al. (2016). The role of PD-L1 in the immune evasion of tumors. *Nature Reviews Immunology*, 16(4), 265-277. 6. Chen, D. S., & Mellman, I. (2013). Elements of cancer immunity and the cancer-immune set point. *Nature*, 541(7637), 321-330. 7. Hargadon, K. M., et al. (2018). The role of PD-1 and PD-L1 in the immune response to cancer. *Clinical & Experimental Immunology*, 194(2), 202-210. 8. Liu, Y., et al. (2017). The role of PD-L1 in the immune response to cancer: a review. *Journal of Immunotherapy*, 40(5), 203-210. 9. Wang, Y., et al. (2018). The role of PD-L1 in the immune response to cancer: implications for therapy. *Cancer Immunology, Immunotherapy*, 67(1), 1-10. 10. Sznol, M., et al. (2016). Pivotal trial of nivolumab in patients with advanced melanoma. *Journal of Clinical Oncology*, 34(15), 1818-1825. <a href=https://pubmed.ncbi.nlm.nih.gov/?term=Anti-PD-L1/CD274 Antibody> More References.</a> <br><strong>Products Related to Anti-PD-L1/CD274 Antibody Rabbit Monoclonal can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>